$207.77
-0.26-0.12%
가까이에: Aug 21, 5:00 PM EST
$207.77
N/A
시간외: Aug 21, 4:00 PM EST
Benzinga
Benzinga
Benzinga
월요일, 8월 24
Axsome Therapeutics Inc
AXSMNASDAQ
Axsome Therapeutics Earnings & Forecasts
Axsome Therapeutics (AXSM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Axsome Therapeutics Guidance
Axsome Therapeutics (AXSM)는 1월 4, 2024에 fiscal year 2023에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $204M - $204M 범위로 예상했습니다.
이전 가이던스와 비교하여 Axsome Therapeutics는 매출 전망치를 이전 범위인 상향 조정됨에서 $71M - $71M로 상향 조정했습니다.
Axsome Therapeutics은 2과 1월 4, 2024 사이에 1월 4, 2024개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.87 | $-0.83 | $-0.72 | $-0.87 |
| Actual | $-0.99 | $-1.26 | $-0.56 | $-0.68 |
| Surprise | -13.8% | -51.8% | +22.2% | +21.8% |
| Revenue | ||||
| Estimate | $222.3M | $190.3M | $193.2M | $163.4M |
| Actual | $218.4M | $191.2M | $196.0M | $171.0M |
| Surprise | -1.77% | +0.48% | +1.47% | +4.64% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.44 | $0.05 | $-0.43 | $0.55 |
| Revenue | ||||
| Consensus | $259.7M | $300.2M | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved